Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade.
Eighty-seven women with advanced cervical carcinoma were treated, in 10 years, with systemic antiblastic chemotherapy using 4 different regimens in 4 successive periods: first VBM, then MAB, CDDP and finally BMFt. Selection of a regimen different than the initial one aimed to obtain a better response and less toxicity. As a whole, 25% positive responses (CR and PR) and an SD which varied from 31.4% to 58.3% were obtained. Among the regimens used, the one with bleomycin, methotrexate and ftorafur had a response rate (OR + SD) of 75% which is higher than what was obtained with regimens VBM and MAB and is similar to CDDP. Less toxicity with greater compliance were shown.
Rigano
A
A
Institute of Gynaecology, University of Messina, Italy.
Adamo
V
V
Altavilla
G
G
d'Aquino
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
D001761:Bleomycin; D005641:Tegafur; D014750:Vincristine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate